{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=6+Gy&page=12", "query": { "intervention": "6 Gy", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 542, "total_pages": 55, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=6+Gy&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=6+Gy&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T03:07:30.043Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03107182", "title": "Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV-Related Squamous Cell Carcinoma", "HNSCC" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Transoral robotic surgery (TORS)", "type": "PROCEDURE" }, { "name": "Adjuvant RT", "type": "RADIATION" }, { "name": "Chemoradiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2017-06-27", "completion_date": "2024-09-06", "has_results": true, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03107182" }, { "nct_id": "NCT05403723", "title": "Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "Durvalumab 50 MG/1 ML Intravenous Solution", "type": "DRUG" }, { "name": "Etoposide Injection", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Stereotactic Body Radiotherapy", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2027-01-30", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05403723" }, { "nct_id": "NCT01041508", "title": "Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia Lymphoblastic, Acute", "Acute Myeloid Leukemia", "Neoplasm Recurrent" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Stem Cell Transplantation", "type": "OTHER" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 18, "start_date": "2010-01-29", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2024-02-01", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 6, "location_summary": "Los Angeles, California • Columbus, Ohio • Portland, Oregon + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01041508" }, { "nct_id": "NCT01040624", "title": "Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "> 15% risk of + LN", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 77, "start_date": "2009-12", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-10-03", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01040624" }, { "nct_id": "NCT07700420", "title": "Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastro-esophageal Junction (GEJ) Cancer", "Esophagus Cancer" ], "interventions": [ { "name": "PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy", "type": "RADIATION" }, { "name": "FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-08-28", "completion_date": "2031-10-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07700420" }, { "nct_id": "NCT04952597", "title": "Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Limited Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Ociperlimab", "type": "DRUG" }, { "name": "Tislelizumab", "type": "DRUG" }, { "name": "Concurrent Chemoradiotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 126, "start_date": "2021-07-15", "completion_date": "2023-07-26", "has_results": true, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 1, "location_summary": "Knoxville, Tennessee", "locations": [ { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04952597" }, { "nct_id": "NCT01852890", "title": "Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "Ascorbate", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Joseph J. Cullen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-01", "completion_date": "2025-10-14", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01852890" }, { "nct_id": "NCT05902533", "title": "REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Anal Cancer" ], "interventions": [ { "name": "Radiation (reduced elective nodal dose (30.6 Gy)", "type": "RADIATION" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Mitomycin c", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2023-08-14", "completion_date": "2029-08-14", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 3, "location_summary": "Cincinnati, Ohio • Columbus, Ohio • Burlington, Vermont", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902533" }, { "nct_id": "NCT01407198", "title": "Nilotinib With Radiation for High Risk Chordoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chordoma" ], "interventions": [ { "name": "Nilotinib", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2011-08", "completion_date": "2025-06", "has_results": false, "last_update_posted_date": "2025-12-19", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01407198" }, { "nct_id": "NCT00402116", "title": "Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Gliosarcoma" ], "interventions": [ { "name": "enzastaurin", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2006-09", "completion_date": "2009-12", "has_results": true, "last_update_posted_date": "2020-08-06", "last_synced_at": "2026-11-02T03:07:30.043Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00402116" } ] }